Artificial Intelligence

March 26, 2026

Hoth Therapeutics Leverages OpenClaw™ AI Platform to Advance Drug Discovery

NASDAQ: $HOTH Hoth Therapeutics Deploys OpenClaw™ AI Platform to Accelerate Drug Discovery Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, has announced a significant strategic advancement with the deployment of OpenClaw™, its new, advanced AI-enabled computational platform. This move signifies a major commitment to integrating artificial intelligence into the core of its drug discovery and development…

Artificial Intelligence

$HOTH, AI in Drug Discovery, Biopharmaceutical Technology, Computational Platform, Hoth Therapeutics, OpenClaw
March 5, 2026

Hoth Therapeutics Leverages OpenAI API to Accelerate Development of Orphan Oncology Program, HT-KIT

NASDAQ: $HOTH Hoth Therapeutics, Inc., a biopharmaceutical company dedicated to patient-focused therapies, recently announced a significant strategic move: the deployment of the OpenAI API to bolster the development of its orphan-designated therapy, HT-KIT. This innovative integration targets rare and aggressive KIT-driven cancers, marking a forward-thinking approach to drug development within the oncology space. AI Integration…

Artificial Intelligence

$HOTH, artificial-intelligence, Biotechnology, Drug Development, oncology, Orphan Drugs
February 7, 2026

Pharos AI and 10x Genomics Join Forces to Advance Cancer Research Through Integrated Technology

NASDAQ: $TXG A significant collaboration has been established between Pharos AI, a leader in artificial intelligence solutions for the life sciences, and 10x Genomics, a pioneer in single cell and spatial biology technologies. This partnership is set to revolutionize how researchers approach complex challenges in oncology by integrating advanced computational power with cutting-edge molecular analysis.…

Artificial Intelligence

$TXG, artificial-intelligence, Cancer Research, Genomics, Spatial Biology, Translational Medicine
February 7, 2026

Metavia’s Collaboration with Syntekabio Yields Positive AI Modeling Results for Vanoglipel

NASDAQ: $MTVA Metavia, Inc., a company focused on novel therapeutic development, recently announced encouraging results stemming from its ongoing artificial intelligence (AI) modeling collaboration with Syntekabio. These latest findings solidify key therapeutic targets relevant to their lead compound, Vanoglipel, a promising drug candidate. The collaboration leverages Syntekabio’s advanced AI platforms to expedite and refine the…

Artificial Intelligence

$MTVA, AI Drug Discovery, Metavia, Syntekabio, Therapeutic Targets, Vanoglipel
December 4, 2023

RxE2 | Revolutionizes Clinical Trials with Groundbreaking AI-led Technology Platform and Marketplace

Introduction In the world of medical advancements, clinical trials play a crucial role in testing new drugs, treatments, and procedures to ensure their safety and efficacy. However, the traditional approach to conducting clinical trials is often time-consuming, costly, and resource-intensive. Enter RxE2, an innovative technology platform and marketplace that is revolutionizing the way clinical trials…

Artificial Intelligence

AI, artificial-intelligence, clinical trials

XBIO REPORT

Category: Artificial Intelligence

Hoth Therapeutics Leverages OpenClaw™ AI Platform to Advance Drug Discovery

Hoth Therapeutics Leverages OpenAI API to Accelerate Development of Orphan Oncology Program, HT-KIT

Pharos AI and 10x Genomics Join Forces to Advance Cancer Research Through Integrated Technology

Metavia’s Collaboration with Syntekabio Yields Positive AI Modeling Results for Vanoglipel

RxE2 | Revolutionizes Clinical Trials with Groundbreaking AI-led Technology Platform and Marketplace